Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genus PLC (GB:GNS)
LSE:GNS
Holding GB:GNS?
Track your performance easily
GNS Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,478.00p - 2,378.00p
Previous Close1,860p
Volume5.87K
Average Volume (3M)86.08K
Market Cap
£1.26B
Enterprise Value1.51B
Total Cash (Recent Filing)£42.50M
Total Debt (Recent Filing)£291.20M
Price to Earnings (P/E)159.6
Beta1.12
Next Earnings
Feb 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Nov 07, 2024Dividend Yield1.67%
Share Statistics
EPS (TTM)0.12
Shares Outstanding66,033,959
10 Day Avg. Volume76,336
30 Day Avg. Volume86,078
Standard Deviation0.09
R-Squared0.00945
Alpha-0.00130
Financial Highlights & Ratios
Price to Book (P/B)224.10
Price to Sales (P/S)1.90
Price to Cash Flow (P/CF)26.60
P/FCF Ratio26.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
2,595.00pPrice Target Upside40.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Genus plc News
PremiumCompany Announcements
Genus plc Reports Total Voting Rights Update
PremiumCompany Announcements
Genus plc CFO to Retire, Successor Search Underway
PremiumCompany Announcements
Genus plc Announces 2024 AGM and Report Availability
PremiumCompany Announcements
Genus plc Executives Sell Shares Post-Vesting
PremiumCompany Announcements
Genus plc CEO Sells Shares for Tax LiabilitiesPremiumCompany Announcements
Genus plc Grants Leadership Team Share Options
PremiumCompany Announcements
Genus PLC Director Buys Company Shares
PremiumCompany Announcements
Genus plc CEO Buys Company SharesBulls Say, Bears Say
Bulls Say
Financial PerformanceCash generation was ahead of expectations.
Market PerformancePIC has performed in line with expectations with robust growth outside China and an improvement in China producer profitability with further royalty wins in that market.
Regulatory ApprovalGenus continues to have positive engagement with the FDA, with approval expected in 2025.
Bears Say
Foreign Exchange ImpactFX headwinds from weakness in the Mexican peso and Brazilian real had previously reduced adjusted profit before tax for FY25 by approximately £5 million.
Profitability ConcernsABS has continued to trade with lower volumes impacting profitability, particularly in China and Brazil.
Revenue PerformanceGenus has reported FY24 results that are in line with the July trading update, confirming a challenging year for the group, with revenue declining 3%.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.31% Insiders
13.99% Mutual Funds
― Other Institutional Investors
78.11% Public Companies and
Individual Investors
GNS FAQ
What was Genus PLC’s price range in the past 12 months?
Genus PLC lowest share price was 1478.00p and its highest was 2378.00p in the past 12 months.
What is Genus PLC’s market cap?
Currently, no data Available
When is Genus PLC’s upcoming earnings report date?
Genus PLC’s upcoming earnings report date is Feb 20, 2025 which is in 102 days.
How were Genus PLC’s earnings last quarter?
Genus PLC released its earnings results on Sep 05, 2024. The company reported -0.085p earnings per share for the quarter, missing the consensus estimate of N/A by -0.085p.
Is Genus PLC overvalued?
According to Wall Street analysts Genus PLC’s price is currently Undervalued.
Does Genus PLC pay dividends?
Genus PLC pays a Annually dividend of 21.7p which represents an annual dividend yield of 1.67%. See more information on Genus PLC dividends here
What is Genus PLC’s EPS estimate?
Genus PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus PLC have?
Genus PLC has 66,034,880 shares outstanding.
What happened to Genus PLC’s price movement after its last earnings report?
Genus PLC reported an EPS of -0.085p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.676%.
Which hedge fund is a major shareholder of Genus PLC?
Currently, no hedge funds are holding shares in GB:GNS
---
Genus plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
2,595.00p (40.27% Upside)
2,595.00p (40.27% Upside)
Insider Transactions
Sold Shares
Worth £189.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.12%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
Genus PLC
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. The company generates most of its revenue from its porcine exposure, followed by its bovine exposure. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency.
---
GNS Stock 12 Month Forecast
Average Price Target
2,595.00p
▲(40.27% Upside)
Technical Analysis
Best Analysts Covering GNS
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+1.87%
reiterated a buy rating last month
Copying Damian McNeela's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +1.87% per trade.
---